Actuate Therapeutics, Inc. Common stock (ACTU NASDAQ) stock market data APIs
$0.332
0.05(15.1%)
as of October 30, 2026
Try our APIs with
free plan!
Actuate Therapeutics, Inc. Common stock Financial Data Overview
Price chart is built with
Anychart
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Prev. Close
0.332
Open
0.3794
High
0.3822
Low
0.3291
52 wk Range
0.33-7.9
Market Cap
20 405 K
Shares Outstanding
54 999 K
EPS
-0.2
Beta
1.2
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Actuate Therapeutics, Inc. Common stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Actuate Therapeutics, Inc. Common stock data using free add-ons & libraries
Get Actuate Therapeutics, Inc. Common stock Fundamental Data
Actuate Therapeutics, Inc. Common stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Actuate Therapeutics, Inc. Common stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -0.21
Get Actuate Therapeutics, Inc. Common stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Actuate Therapeutics, Inc. Common stock News
New
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Teva Pharmaceutical Industries Limited TEVA announced that the FDA has approved Weltruza (olanzapine) extended-release injectable suspension for the treatment of schizophrenia in adults. Following th...
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
AbbVie ABBV announced that the FDA has granted two Breakthrough Therapy designations (BTDs) to its investigational next-generation antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A; ABB...
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus
(RTTNews) - Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botens...
Pre-Market Movers: PMI, CNTB, RNAZ Chart The Course
(RTTNews) - Pre-market trading is offering an early glimpse into biotech stocks likely to attract investor attention this Wednesday. Significant price moves ahead of the opening bell are being driven...
Get Actuate Therapeutics, Inc. Common stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.